TN-NASHVILLE-SOCCER-CLUB
As Nashville Soccer Club enters its fourth season in Major League Soccer, and second at GEODIS Park, principal owner John Ingram announced today that leading scorer in Nashville Predator history Filip Forsberg and two-time MVP and NBA Champion Giannis Antetokounmpo have joined the team’s ownership group.
Antetokounmpo is joined in ownership by his brothers Thanasis, Kostas and Alex as well – all of whom play professional basketball worldwide. Thanasis joined Giannis in winning the NBA Championship with the Milwaukee Bucks in 2021, and Kostas won one with the Los Angeles Lakers in 2020.
The announcement of the new owners continues the strong momentum built by Nashville SC in the lead-up to the 2023 season, highlighted by its 'Man in Black’ jersey collaboration with the Estate of Johnny Cash. That momentum continued with a 2-0 victory over New York City FC in front of 28,051 fans at GEODIS Park this past Saturday.
Forsberg and Antetokounmpo join a robust and diverse ownership group whose most recent additions include Reese Witherspoon, her husband Jim Toth and Derrick Henry.
“Nashville is the best sports city in the country, and I am extremely blessed to now be involved with two of our pro teams,” said Forsberg. “Our city is one big family and fanbase, and we support each other on and off the field. Nashville SC has been such a great addition to our sports culture, and joining the ownership group was an opportunity I wasn’t going to pass up. I grew up a Liverpool FC fan in Sweden, and after today I am happy to add a second set of colors to cheer for!”
“My father was a professional soccer player, and it was the first sport I fell in love with in Greece,” said Antetokounmpo. “I’ve always had the dream of owning a soccer team. When my brothers and I explored Nashville SC, we knew it was a team and a city that we wanted to get involved with. I couldn’t be more excited to join the Boys in Gold, and can’t wait to come to a match at GEODIS Park soon!”
“Soccer is a global sport, and our newest owners once again reinforce our club’s commitment to being a global team,” said Ingram. “Filip and Giannis are not just amazing athletes – they are ambassadors for their respective sports, role models for millions and advocates in their hometowns and worldwide. We share a common belief that our teams not only play to the highest standards, but also lift up their communities and help those who need it most.”
Nashville SC takes on the road to face the New York Red Bulls at 6:30 p.m. CT on Saturday, March 4. Fans ns can follow the action on the MLS Season Pass on the Apple TV app and the club on its digital and social channels on Instagram, Facebook, TikTok, Twitter and Spotify.
MEDIA RESOURCES:
- Nashville SC Media Center with news, b-roll from training, match notes, other video and photo resources
- Media looking to follow NSC on social media can find the club on TikTok, Twitter and Instagram with the handle @NashvilleSC. For Facebook and YouTube please use “Nashville Soccer Club”
- The official club hashtag when referring to Nashville SC on social media is #EveryoneN
FOR MORE INFORMATION, CONTACT: Zach Hunt, zach@tsgnashville.com, 615.321.3110.
About Nashville SC
Nashville SC joined Major League Soccer on Feb. 29, 2020 in front of the largest attendance ever recorded for a soccer match in the State of Tennessee. In its inaugural MLS season, Nashville SC defeated expectations by becoming the second MLS expansion side to win and advance to the Conference Semifinals in the 2020 Audi MLS Cup Playoffs. Nashville SC returned to the 2021 Audi MLS Cup Playoffs in its sophomore season after becoming just the seventh team in MLS history to go unbeaten at home in a season. Nashville SC inaugurated GEODIS Park, the largest soccer-specific stadium in the United States and Canada, in front of a 30,109-sellout crowd on May 1, 2022. For more information, visit NashvilleSC.com and follow the club at @NashvilleSC on Instagram, Facebook, Twitter and Spotify.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005537/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
